| cpd00782 | 544477-17-0 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | GRPAK | p-Toluenesulfonamide | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI |
cpd00783 | 202411-01-6 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | RPAK | p-Toluenesulfonamide | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI | cpd00784 | 1305119-21-4 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XQRPAK | b-carboline alkaloid | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI | cpd00785 | 1305119-19-0 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XQRPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00786 | 1305119-17-8 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XQRPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00787 | 1305119-15-6 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XGRPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00788 | 1305119-12-3 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XGRPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00789 | 1305119-07-6 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XGRPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00790 | 1305119-05-4 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XARPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00791 | 1305119-03-2 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XARPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00792 | 1305119-01-0 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XARPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00793 | 1305118-97-1 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XQXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00794 | 1305118-93-7 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XQXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00795 | 1305118-91-5 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XQXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00796 | 1305118-89-1 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XGXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00797 | 1305118-86-8 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XGXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00798 | 1305118-81-3 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XGXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00799 | 1305118-78-8 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XAXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00800 | 1305118-75-5 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XAXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00801 | 1305118-72-2 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | XAXPAK | b-carboline alkaloid | Anti-thrombolytic therapy | amide | Bi, Wei;et.al (2011)
DOI | cpd00802 | 202411-02-7 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | RPAK | p-Toluenesulfonamide | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI | cpd00803 | 860020-50-4 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | ARPAK | p-Toluenesulfonamide | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI | cpd00804 | 860020-52-6 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | QRPAK | p-Toluenesulfonamide | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI | cpd00805 | 860020-51-5 | pentapeptide generated by plasmin degradation from the fibrinogen beta chain | GRPAK | p-Toluenesulfonamide | Anti-thrombolytic therapy | sulfonamide | Bi, Wei;et.al (2011)
DOI | cpd00806 | 1335233-73-2 | tripeptide | XAAK | porphyrin-derivative | design of DNA-targeted porphyrin–peptide conjugates | amide | Mezo, Gabor;et.al (2011)
DOI | cpd00807 | 1335233-72-1 | tripeptide | XAAK | porphyrin-derivative | design of DNA-targeted porphyrin–peptide conjugates | amide | Mezo, Gabor;et.al (2011)
DOI | cpd00808 | 1283096-36-5 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide | Anticancer therapy, A549 and HL-60 cells) | sulfonamide | Kukowska-et.al (2011)
DOI | cpd00809 | 1283096-69-4 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00810 | 1283096-68-3 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00811 | 1283096-67-2 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | 
